Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKinsey
Johnson and Johnson
Medtronic
Dow

Last Updated: February 2, 2023

Lamotrigine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for lamotrigine and what is the scope of patent protection?

Lamotrigine is the generic ingredient in five branded drugs marketed by Glaxosmithkline Llc, Actavis Elizabeth, Amneal Pharms, Anchen Pharms, Dr Reddys Labs Ltd, Par Pharm, Rubicon, Torrent, Wockhardt Bio Ag, Yiling, Zydus Pharms, Alembic Pharms Ltd, Aurobindo Pharma, Glenmark Pharms Ltd, Jubilant Generics, Mylan, Sandoz, Taro, Teva, Watson Labs, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Amring Pharms, Impax Labs Inc, Sciegen Pharms Inc, Actavis Totowa, Alkem Labs Ltd, Cipla, Glenmark Generics, Granules, Hikma Pharms, Jubilant Cadista, Lupin Ltd, Mylan Labs Ltd, Rising, Roxane, Taro Pharm Inds, Torrent Pharms, Unichem Labs Ltd, Zennova, and Zydus Pharms Usa, and is included in fifty-three NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lamotrigine has ninety-five patent family members in thirty-eight countries.

There are thirty-two drug master file entries for lamotrigine. Forty-eight suppliers are listed for this compound. There are three tentative approvals for this compound.

Drug Prices for lamotrigine

See drug prices for lamotrigine

Drug Sales Revenue Trends for lamotrigine

See drug sales revenues for lamotrigine

Recent Clinical Trials for lamotrigine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Westfälische Wilhelms-Universität MünsterPhase 4
Dr. Inge WinterPhase 4
Region Capital DenmarkN/A

See all lamotrigine clinical trials

Generic filers with tentative approvals for LAMOTRIGINE
Applicant Application No. Strength Dosage Form
See Plans and PricingSee Plans and Pricing25MGTABLET;ORAL
See Plans and PricingSee Plans and Pricing200MGTABLET;ORAL
See Plans and PricingSee Plans and Pricing150MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for LAMOTRIGINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LAMICTAL XR Extended-release Tablets lamotrigine 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg 022115 1 2014-02-12
LAMICTAL ODT Orally Disintegrating Tablets lamotrigine 25 mg, 50 mg, 100 mg, and 200 mg 022251 1 2009-12-21

US Patents and Regulatory Information for lamotrigine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm LAMOTRIGINE lamotrigine TABLET, EXTENDED RELEASE;ORAL 201791-005 Jan 18, 2013 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Taro Pharm Inds LAMOTRIGINE lamotrigine TABLET;ORAL 078525-002 Jan 27, 2009 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rising LAMOTRIGINE lamotrigine TABLET;ORAL 077420-004 Jan 27, 2009 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Dr Reddys Labs Ltd LAMOTRIGINE lamotrigine TABLET, EXTENDED RELEASE;ORAL 202383-006 Sep 6, 2018 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Unichem Labs Ltd LAMOTRIGINE lamotrigine TABLET;ORAL 090170-003 Oct 6, 2011 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Mylan Labs Ltd LAMOTRIGINE lamotrigine TABLET;ORAL 078443-001 Feb 11, 2009 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for lamotrigine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc LAMICTAL lamotrigine TABLET;ORAL 020241-004 Dec 27, 1994 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-002 Aug 24, 1998 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-004 Sep 8, 2000 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL lamotrigine TABLET;ORAL 020241-005 Dec 27, 1994 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL lamotrigine TABLET;ORAL 020241-006 Dec 27, 1994 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-003 Aug 24, 1998 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for lamotrigine

Country Patent Number Title Estimated Expiration
Portugal 1524981 See Plans and Pricing
Malaysia 141049 SUSTAINED RELEASE FORMULATIONS COMPRISING LAMOTRIGINE See Plans and Pricing
United Kingdom 0313801 See Plans and Pricing
Japan 2010159301 ORAL DOSAGE FORM FOR CONTROLLED DRUG RELEASE See Plans and Pricing
Morocco 27689 See Plans and Pricing
China 1681509 Slow release preparation containing larmotriazine See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
AstraZeneca
Moodys
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.